Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

11 Further, pooled analysis of the TNT and IDEAL trials showed a trend for decreased CV event risk with lowering of triglycerides ( P < 0.001), although this was attenuated by adjustment for HDL-C and the ratio of apo B/apo A–I. 104 In T2DM patients, the FIELD and ACCORD Lipid studies showed that marked atherogenic dyslipidaemia (triglycerides ≥2.3 mmol/L or 204 mg/dL

also in 53,322 other papers